609 related articles for article (PubMed ID: 25425713)
21. Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care.
Reznicek L; Muhr J; Ulbig M; Kampik A; Mayer WJ; Haritoglou C; Neubauer A; Wolf A
Br J Ophthalmol; 2014 Oct; 98(10):1333-7. PubMed ID: 24903670
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
23. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
[TBL] [Abstract][Full Text] [Related]
24. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme.
Heimes B; Lommatzsch A; Zeimer M; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):639-44. PubMed ID: 20890777
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
26. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
Gomi F; Sawa M; Tsujikawa M; Nishida K
Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
[TBL] [Abstract][Full Text] [Related]
27. Switch from intravitreal ranibizumab to bevacizumab for the treatment of neovascular age-related macular degeneration: clinical comparison.
Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Brandão EM; Falcão-Reis F; Carneiro AM
Ophthalmologica; 2014; 232(3):149-55. PubMed ID: 25196907
[TBL] [Abstract][Full Text] [Related]
28. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
[TBL] [Abstract][Full Text] [Related]
29. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
[TBL] [Abstract][Full Text] [Related]
30. LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration.
Ranchod TM; Ray SK; Daniels SA; Leong CJ; Ting TD; Verne AZ
Retina; 2013 Sep; 33(8):1600-4. PubMed ID: 23549100
[TBL] [Abstract][Full Text] [Related]
31. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema.
Zucchiatti I; Lattanzio R; Querques G; Querques L; Del Turco C; Cascavilla ML; Bandello F
Ophthalmologica; 2012; 228(2):117-22. PubMed ID: 22310491
[TBL] [Abstract][Full Text] [Related]
33. Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome.
Dutra Medeiros M; Navarro R; Garcia-Arumí J; Mateo C; Corcóstegui B
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3320-4. PubMed ID: 23599334
[TBL] [Abstract][Full Text] [Related]
34. REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome.
Gianniou C; Dirani A; Jang L; Mantel I
Retina; 2015 Jun; 35(6):1195-201. PubMed ID: 25650710
[TBL] [Abstract][Full Text] [Related]
35. Fixation stability measurements in patients with neovascular age-related macular degeneration treated with ranibizumab.
Grenga PL; Fragiotta S; Meduri A; Lupo S; Marenco M; Vingolo EM
Can J Ophthalmol; 2013 Oct; 48(5):394-9. PubMed ID: 24093186
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.
Cho HJ; Koh KM; Kim JH; Kim HS; Han JI; Lew YJ; Lee TG; Kim JW
Retina; 2015 Feb; 35(2):205-12. PubMed ID: 25105310
[TBL] [Abstract][Full Text] [Related]
38. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
Lee SJ; Koh HJ
Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
Peden MC; Suñer IJ; Hammer ME; Grizzard WS
Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
